Virtually all available studies pooled together BRCA1- and BRCA2-mutated cancers; this approach may be acceptable for the evaluation of the treatment outcomes for BRCA1/2-specific agents (anthracyclines, platinum drugs, mitomycin C, PARP inhibitors), but is questionable while considering the analysis of efficacy of taxanes or some other drugs. Here, BRCA2 is linked to cancer.